Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune... see more

Bullboard (TSX:ONC)

View:
Comment by Azzak34on Apr 22, 2024 1:16pm

RE:RE:Ok

Haha Bucky has given us the all clear folks.... forge ahead.  Oh and it's nice that one of our biggest, albeit dumbest, detractors thinks $5 billion is reality. What a day, what a day ...more  
Comment by Buckhenryon Apr 22, 2024 1:08pm

RE:Ok

Good to see the pumpers finally coming back to reality on buyout price. Was not long ago they were 10 to 25B. Now can we continue the discussion on capital gains!!!
Post by canadafanon Apr 22, 2024 12:34pm

News before end of this quarter?

I agree 100% with the many comparables that notable has enlighten this board with. The $1-$5 billion range of acquisitions is happening in the biotech world. The pharma companies are doing well with ...more  
Post by Lesalpes29on Apr 22, 2024 11:24am

Ok

Added some. Let Matt get us a surprise before this quarter end. 
Comment by Noteableon Apr 22, 2024 11:10am

RE:RE:RE:RE:PwC sees continuation of US$ 5 to 15 Billion Bio M&A Deals

The number of patients at later time points in the Alpine Immune Science povetacicept phase 1b clinical trial, now reported as a Phase 3 ready clinical candidate, is only six patients in the 80mg dose ...more  
Comment by Noteableon Apr 22, 2024 10:55am

RE:RE:RE:PwC sees continuation of US$ 5 to 15 Billion Bio M&A Deals

As posted on April 11, 2024 - Vertex Pharmaceuticals is acquiring Phase 1b Alpine Immune Sciences for $4.9 billion, gaining access to povetacicept, a potential treatment for IgA nephropathy and up to ...more  
Comment by Noteableon Apr 22, 2024 9:41am

RE:RE:EU Legislative proposals aims to expedite new medicines

As concluded, this newly affected collaborated effort by international governments to reduce international "red-tape" and facilitate collective international regulatory decision-making for ...more  
Comment by Lesalpes29on Apr 22, 2024 9:09am

RE:RE:RE:Peladumdum...

OK I stop. Just add one more clown on my ignore list. Now I can only read CFan Johnny Casey loll!
Comment by Lesalpes29on Apr 22, 2024 9:01am

RE:RE:Peladumdum...

11 peladumdum pelastupidos! And so on...
Comment by 13X2413on Apr 22, 2024 9:01am

RE:RE:Peladumdum...

Shouldn't it be nap time at your daycare. Kids, stop fighting!  Mommy and Daddy aren't going to be happy with your behaviour.  SH admin. Get rid of this BS!!
Comment by Peladawnon Apr 22, 2024 8:51am

RE:Peladumdum...

Peladumdum?!....lol.....what are you Les...12 years old?
Post by Lesalpes29on Apr 22, 2024 8:38am

Peladumdum...

Working hard with your small brain...
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities